Lazard Asset Management
ABEO icon

Lazard Asset Management’s Abeona Therapeutics ABEO Stock Holding History

Lazard Asset Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-116
Closed – – 2277
2024
Q4 		$0 Hold
116
– – ﹤0.01% 2250
2024
Q3 		$0 Sell
116
-47
-29% -$245 ﹤0.01% 2242
2024
Q2 		$0 Sell
163
-961
-85% -$4.9K ﹤0.01% 2201
2024
Q1 		$7K Buy
+1,124
New +$7.12K ﹤0.01% 1883

Other funds holding ABEO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Lazard Asset Management's ABEO Position: Q1 2025 in Review

Lazard Asset Management sold out of Abeona Therapeutics (ABEO) in Q1 2025, closing a stake of 116 shares.

Lazard Asset Management first reported a position in ABEO in Q1 2024 and held it in 4 quarters. The position peaked at $7K in Q1 2024. 71 funds tracked by Wall St. Rank hold ABEO as of Q1 2025.

  • Lazard Asset Management reported no remaining Abeona Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 116 Abeona Therapeutics shares in Q1 2025.
  • Lazard Asset Management first reported a position in Abeona Therapeutics in Q1 2024 and held it in 4 quarters.
  • Lazard Asset Management's Abeona Therapeutics position peaked at $7K in Q1 2024.
  • 71 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.